Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All molnupiravir studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchMolnupiravirMolnupiravir (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   All Outcomes    Recent:   

Molnupiravir Inhibits Replication of the Emerging SARS-CoV-2 Variants of Concern in a Hamster Infection Model

Abdelnabi et al., The Journal of Infectious Diseases, doi:10.1093/infdis/jiab361
Jul 2021  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Hamster study showing molnupiravir effective against the original, B.1.1.7, and B.1.351 variants.
Concerns have been raised that the mutagenic mechanism of action may create dangerous variants or cause cancer1-9. Multiple analyses have identified variants potentially created by molnupiravir10-13.
Abdelnabi et al., 9 Jul 2021, peer-reviewed, 6 authors.
This PaperMolnupiravirAll
{ 'indexed': {'date-parts': [[2024, 5, 12]], 'date-time': '2024-05-12T01:11:23Z', 'timestamp': 1715476283292}, 'reference-count': 15, 'publisher': 'Oxford University Press (OUP)', 'issue': '5', 'license': [ { 'start': { 'date-parts': [[2021, 7, 9]], 'date-time': '2021-07-09T00:00:00Z', 'timestamp': 1625788800000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by/4.0/'}], 'funder': [ { 'DOI': '10.13039/501100004040', 'name': 'Katholieke Universiteit Leuven', 'doi-asserted-by': 'publisher'}, { 'DOI': '10.13039/501100010648', 'name': 'Universitair Ziekenhuis Leuven', 'doi-asserted-by': 'crossref'}, { 'DOI': '10.13039/501100003130', 'name': 'Fonds Wetenschappelijk Onderzoek', 'doi-asserted-by': 'publisher', 'award': ['G0G4820N']}, { 'DOI': '10.13039/501100000780', 'name': 'European Union', 'doi-asserted-by': 'publisher', 'award': ['101003627']}, { 'DOI': '10.13039/100000865', 'name': 'Bill and Melinda Gates Foundation', 'doi-asserted-by': 'publisher', 'award': ['INV-00636']}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'published-print': {'date-parts': [[2021, 9, 1]]}, 'abstract': '<jats:title>Abstract</jats:title><jats:p>The emergence of SARS-CoV-2 variants of concern ' '(VoCs) has exacerbated the COVID-19 pandemic. Currently available monoclonal antibodies and ' 'vaccines appear to have reduced efficacy against some of these VoCs. Antivirals targeting ' 'conserved proteins of SARS-CoV-2 are unlikely to be affected by mutations arising in VoCs and ' 'should therefore be effective against emerging variants. We here investigate the efficacy of ' 'molnupiravir, currently in phase 2 clinical trials, in hamsters infected with Wuhan strain or ' 'B.1.1.7 and B.1.351 variants. Molnupiravir proved to be effective against infections with ' 'each of the variants and therefore may have potential combating current and future emerging ' 'VoCs.</jats:p>', 'DOI': '10.1093/infdis/jiab361', 'type': 'journal-article', 'created': {'date-parts': [[2021, 7, 8]], 'date-time': '2021-07-08T19:13:00Z', 'timestamp': 1625771580000}, 'page': '749-753', 'source': 'Crossref', 'is-referenced-by-count': 99, 'title': 'Molnupiravir Inhibits Replication of the Emerging SARS-CoV-2 Variants of Concern in a Hamster ' 'Infection Model', 'prefix': '10.1093', 'volume': '224', 'author': [ { 'given': 'Rana', 'family': 'Abdelnabi', 'sequence': 'first', 'affiliation': [ { 'name': 'Laboratory of Virology and Chemotherapy, Department of ' 'Microbiology, Immunology and Transplantation, Rega Institute for ' 'Medical Research, Katholieke Universiteit Leuven, Leuven, ' 'Belgium'}]}, { 'given': 'Caroline S', 'family': 'Foo', 'sequence': 'additional', 'affiliation': [ { 'name': 'Laboratory of Virology and Chemotherapy, Department of ' 'Microbiology, Immunology and Transplantation, Rega Institute for ' 'Medical Research, Katholieke Universiteit Leuven, Leuven, ' 'Belgium'}]}, { 'given': 'Steven', 'family': 'De Jonghe', 'sequence': 'additional', 'affiliation': [ { 'name': 'Laboratory of Virology and Chemotherapy, Department of ' 'Microbiology, Immunology and Transplantation, Rega Institute for ' 'Medical Research, Katholieke Universiteit Leuven, Leuven, ' 'Belgium'}]}, { 'ORCID': 'http://orcid.org/0000-0001-9118-8608', 'authenticated-orcid': False, 'given': 'Piet', 'family': 'Maes', 'sequence': 'additional', 'affiliation': [ { 'name': 'Laboratory of Clinical and Epidemiological Virology, Department ' 'of Microbiology, Immunology and Transplantation, Rega Institute, ' 'Katholieke Universiteit Leuven, Leuven, Belgium'}, {'name': 'Zoonotic Infectious Diseases Unit, KU Leuven, Leuven, Belgium'}]}, { 'given': 'Birgit', 'family': 'Weynand', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Imaging and Pathology, Division of Translational ' 'Cell and Tissue Research, Katholieke Universiteit Leuven, ' 'Leuven, Belgium'}]}, { 'given': 'Johan', 'family': 'Neyts', 'sequence': 'additional', 'affiliation': [ { 'name': 'Laboratory of Virology and Chemotherapy, Department of ' 'Microbiology, Immunology and Transplantation, Rega Institute for ' 'Medical Research, Katholieke Universiteit Leuven, Leuven, ' 'Belgium'}, {'name': 'Global Virus Network, Baltimore, Maryland, USA'}]}], 'member': '286', 'published-online': {'date-parts': [[2021, 7, 9]]}, 'reference': [ { 'key': '2021090109221259500_CIT0001', 'doi-asserted-by': 'crossref', 'first-page': '727', 'DOI': '10.1056/NEJMoa2001017', 'article-title': 'A novel coronavirus from patients with pneumonia in China, 2019', 'volume': '382', 'author': 'Zhu', 'year': '2020', 'journal-title': 'N Engl J Med'}, { 'key': '2021090109221259500_CIT0002', 'doi-asserted-by': 'crossref', 'first-page': '508', 'DOI': '10.1016/j.chom.2021.02.020', 'article-title': 'The variant gambit: COVID-19’s next move', 'volume': '29', 'author': 'Plante', 'year': '2021', 'journal-title': 'Cell Host Microbe'}, { 'key': '2021090109221259500_CIT0003', 'doi-asserted-by': 'crossref', 'first-page': '452', 'DOI': '10.1016/S0140-6736(21)00183-5', 'article-title': 'Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence', 'volume': '397', 'author': 'Sabino', 'year': '2021', 'journal-title': 'Lancet'}, { 'key': '2021090109221259500_CIT0004', 'doi-asserted-by': 'crossref', 'first-page': 'n359', 'DOI': '10.1136/bmj.n359', 'article-title': 'Covid-19: the E484K mutation and the risks it poses', 'volume': '372', 'author': 'Wise', 'year': '2021', 'journal-title': 'BMJ'}, { 'key': '2021090109221259500_CIT0005', 'doi-asserted-by': 'crossref', 'first-page': 'e01965-17', 'DOI': '10.1128/JVI.01965-17', 'article-title': 'β-d-N4-hydroxycytidine is a potent anti-alphavirus compound that ' 'induces a high level of mutations in the viral genome', 'volume': '92', 'author': 'Urakova', 'year': '2017', 'journal-title': 'J Virol'}, { 'key': '2021090109221259500_CIT0006', 'doi-asserted-by': 'crossref', 'first-page': 'eaax5866', 'DOI': '10.1126/scitranslmed.aax5866', 'article-title': 'Characterization of orally efficacious influenza drug with high ' 'resistance barrier in ferrets and human airway epithelia', 'volume': '11', 'author': 'Toots', 'year': '2019', 'journal-title': 'Sci Transl Med'}, { 'key': '2021090109221259500_CIT0007', 'article-title': 'The combined treatment of molnupiravir and favipiravir results in a ' 'marked potentiation of antiviral efficacy in a SARS-CoV-2 hamster ' 'infection model', 'author': 'Abdelnabi', 'year': '10', 'journal-title': 'bioRxiv'}, { 'key': '2021090109221259500_CIT0008', 'doi-asserted-by': 'crossref', 'DOI': '10.1038/s41586-021-03312-w', 'article-title': 'SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801', 'author': 'Wahl', 'year': '2021', 'journal-title': 'Nature'}, { 'key': '2021090109221259500_CIT0009', 'doi-asserted-by': 'crossref', 'first-page': '11', 'DOI': '10.1038/s41564-020-00835-2', 'article-title': 'Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 ' 'blocks SARS-CoV-2 transmission in ferrets', 'volume': '6', 'author': 'Cox', 'year': '2021', 'journal-title': 'Nat Microbiol'}, { 'key': '2021090109221259500_CIT0010', 'doi-asserted-by': 'crossref', 'first-page': 'e02428-20', 'DOI': '10.1128/AAC.02428-20', 'article-title': 'Human safety, tolerability, and pharmacokinetics of molnupiravir, a ' 'novel broad-spectrum oral antiviral agent with activity against ' 'SARS-CoV-2', 'volume': '65', 'author': 'Painter', 'year': '2021', 'journal-title': 'Antimicrob Agents Chemother'}, { 'key': '2021090109221259500_CIT0011', 'article-title': 'Reduction in infectious SARS-CoV-2 in treatment study of COVID-19 with ' 'molnupiravir', 'author': 'Painter'}, { 'key': '2021090109221259500_CIT0012', 'doi-asserted-by': 'crossref', 'first-page': '103403', 'DOI': '10.1016/j.ebiom.2021.103403', 'article-title': 'Comparing infectivity and virulence of emerging SARS-CoV-2 variants in ' 'Syrian hamsters', 'volume': '68', 'author': 'Abdelnabi', 'year': '2021', 'journal-title': 'EBioMedicine'}, { 'key': '2021090109221259500_CIT0013', 'doi-asserted-by': 'crossref', 'first-page': '130', 'DOI': '10.1038/s41586-021-03398-2', 'article-title': 'Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7', 'volume': '593', 'author': 'Wang', 'year': '2021', 'journal-title': 'Nature'}, { 'key': '2021090109221259500_CIT0014', 'doi-asserted-by': 'crossref', 'first-page': '329', 'DOI': '10.1126/science.371.6527.329', 'article-title': 'New mutations raise specter of ‘immune escape’', 'volume': '371', 'author': 'Kupferschmidt', 'year': '2021', 'journal-title': 'Science'}, { 'key': '2021090109221259500_CIT0015', 'doi-asserted-by': 'crossref', 'first-page': '82', 'DOI': '10.1016/j.coviro.2021.03.010', 'article-title': 'Structure and function of SARS-CoV-2 polymerase', 'volume': '48', 'author': 'Hillen', 'year': '2021', 'journal-title': 'Curr Opin Virol'}], 'container-title': 'The Journal of Infectious Diseases', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'http://academic.oup.com/jid/advance-article-pdf/doi/10.1093/infdis/jiab361/39721682/jiab361.pdf', 'content-type': 'application/pdf', 'content-version': 'am', 'intended-application': 'syndication'}, { 'URL': 'http://academic.oup.com/jid/article-pdf/224/5/749/40166589/jiab361.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'syndication'}, { 'URL': 'http://academic.oup.com/jid/article-pdf/224/5/749/40166589/jiab361.pdf', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2023, 1, 3]], 'date-time': '2023-01-03T11:35:22Z', 'timestamp': 1672745722000}, 'score': 1, 'resource': {'primary': {'URL': 'https://academic.oup.com/jid/article/224/5/749/6318434'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2021, 7, 9]]}, 'references-count': 15, 'journal-issue': { 'issue': '5', 'published-online': {'date-parts': [[2021, 7, 9]]}, 'published-print': {'date-parts': [[2021, 9, 1]]}}, 'URL': 'http://dx.doi.org/10.1093/infdis/jiab361', 'relation': {}, 'ISSN': ['0022-1899', '1537-6613'], 'subject': [], 'published-other': {'date-parts': [[2021, 9, 1]]}, 'published': {'date-parts': [[2021, 7, 9]]}}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit